Core Viewpoint - Shandong Weiming Pharmaceutical Co., Ltd. faces significant operational challenges due to the suspension of production and sales at its subsidiary Tianjin Weiming Biopharmaceutical Co., Ltd., leading to a risk warning for its stock and a change in trading status to "ST Weiming" [1][3]. Group 1: Stock Trading and Risk Warnings - Tianjin Weiming was subjected to risk control measures on April 22, 2025, and is expected to be unable to resume normal operations within three months as of July 4, 2025, triggering a risk warning under the Shenzhen Stock Exchange regulations [1][3]. - The company's stock price experienced a cumulative decline of 15.82% over three consecutive trading days starting July 8, 2025, indicating abnormal trading fluctuations [1][2]. Group 2: Financial Impact and Company Performance - In 2024, Tianjin Weiming generated revenue of RMB 216.57 million and incurred a net loss of RMB 14.00 million, accounting for 60.09% of the company's total revenue and 9.8% of the consolidated net profit [2]. - For the fiscal year 2024, the company reported total revenue of RMB 360.41 million and a net loss attributable to shareholders of RMB 137.31 million, with the first quarter of 2025 showing revenue of RMB 35.33 million and a continued net loss [3].
ST未名: 关于股价异动及风险提示的公告